INTESTINAL LIPOMATOSIS

This adverse event was reported 13 times

These drugs are most commonly taken by patients reporting INTESTINAL LIPOMATOSIS:

# Drug Count
0 ATEZOLIZUMAB 2
1 BEVACIZUMAB 2
2 CARBOPLATIN 2
3 PACLITAXEL 2
4 PACLITAXEL (AIBUMIN-BOUND) 2
5 RISANKIZUMAB-RZAA 2
6 VEDOLIZUMAB 2
7 ADALIMUMAB 1
8 CETIRIZINE HYDROCHLORIDE 1
9 EVOLOCUMAB 1
See all common drugs associated with INTESTINAL LIPOMATOSIS

INTESTINAL LIPOMATOSIS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 SODIUM SULFATE, MAGNESIUM SULFATE, AND POTASSIUM CHLORIDE 1 0.0006
1 INFLIXIMAB-DYYB 1 0.0003
2 SODIUM SULFATE, POTASSIUM SULFATE, MAGNESIUM SULFATE 1 0.0002
3 ATEZOLIZUMAB 2 0.0001
4 MESALAMINE 1 0.0000
5 VEDOLIZUMAB 2 0.0000
6 PACLITAXEL 2 0.0000
7 BEVACIZUMAB 2 0.0000
8 CARBOPLATIN 2 0.0000
9 FLUCONAZOLE 1 0.0000
See all drugs enriched for association with INTESTINAL LIPOMATOSIS

INTESTINAL LIPOMATOSIS is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Integrin Receptor Antagonist [EPC] 2 0.0000
1 Microtubule Inhibitor [EPC] 2 0.0000
2 Vascular Endothelial Growth Factor Inhibitor [EPC] 2 0.0000
3 Aminosalicylate [EPC] 1 0.0000
4 Platinum-based Drug [EPC] 2 0.0000
5 Azole Antifungal [EPC] 1 0.0000
6 Loop Diuretic [EPC] 1 0.0000
7 Tumor Necrosis Factor Blocker [EPC] 1 0.0000
8 Corticosteroid [EPC] 1 0.0000
See all drug classes enriched for association with INTESTINAL LIPOMATOSIS